Market Place
Sourcing Support
Shorla Oncology Announces FDA Approval of JYLAMVO™ for Pediatrics
29 Oct 2024 //
BUSINESSWIRE
Shorla Oncology Announces FDA Approval for TEPYLUTE in Breast and Ovarian Cancer
28 Jun 2024 //
BUSINESSWIRE
Shorla Announces FDA Filing Acceptance of NDA to Treat Certain Forms of Leukemia
08 Apr 2024 //
BUSINESSWIRE
Shorla Oncology Announces FDA Filing Acceptance of NDA to Treat Breast Cancer
09 Jan 2024 //
BUSINESSWIRE
Shorla & EVERSANA Announce U.S. Commercial Launch of FDA-Approved JYLAMVO
19 Dec 2023 //
PR NEWSWIRE
Shorla Oncology Welcomes Rayna Sethi Herman as Chief Commercial Officer
07 Dec 2023 //
BUSINESSWIRE
Shorla Oncology Announces US Acquisition of Jylamvo
31 Oct 2023 //
BUSINESSWIRE
Shorla Oncology Secures $35M Series B Funding Round
04 Oct 2023 //
BUSINESSWIRE
Shorla Oncology Announces Partnership for Rights to Market Drug, PIP-101
06 Jul 2023 //
BUSINESSWIRE
Shorla Oncology & EVERSANA Announce Launch of Recent FDA-Approved Nelarabine Inj
16 May 2023 //
PR NEWSWIRE
Shorla Pharma Announces Partnership with EVERSANA
17 Aug 2021 //
PRNEWSWIRE
Shorla Announces FDA Filing Acceptance and Priority Review for T-cell Leukemia
23 Apr 2021 //
BUSINESSWIRE
Shorla Announces FDA Filing Acceptance and Priority Review for T-cell Leukemia
22 Apr 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.